Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 4/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 6/20 | 0.68 |
| ▸ | DRD2 | P14416 | 5/20 | 0.68 |
| ▸ | DRD3 | P35462 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.68 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7799623 | 0.91 | ADRA1A (0.83) | ADRA1AADRA1BADRA1DCYP3A4ADRA2A | |
| SCHEMBL7801653 | 0.88 | ADRA1A (0.79) | ADRA1AADRA1BADRA1DCYP3A4ADRA2A | |
| SCHEMBL8053702 | 0.86 | ADRA1A (0.76) | ADRA1AADRA1BADRA1DCYP3A4ADRA2A | |
| SCHEMBL7793938 | 0.86 | ADRA1A (0.75) | ADRA1AADRA1BADRA1DCYP3A4ADRA2A | |
| SCHEMBL7801661 | 0.86 | ADRA1A (0.75) | ADRA1AADRA1BADRA1DCYP3A4ADRA2A | |
| SCHEMBL7799617 | 0.85 | ADRA1B (0.74) | ADRA1AADRA1BADRA1DCYP3A4ADRA2A | |
| SCHEMBL7803792 | 0.85 | ADRA1A (0.73) | ADRA1AADRA1BADRA1DCYP3A4ADRA2A | |
| SCHEMBL7803666 | 0.85 | ADRA1A (0.73) | ADRA1AADRA1BADRA1DCYP3A4ADRA2A | |
| SCHEMBL8053704 | 0.85 | ADRA1A (0.73) | ADRA1AADRA1BADRA1DCYP3A4ADRA2A | |
| SCHEMBL7803659 | 0.85 | ADRA1A (0.73) | ADRA1AADRA1BADRA1DCYP3A4ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192319-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-10-05 | — | — | WO | claimed |
| EP-0513058-A1 | USE OF KNOWN URACILES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROTECTION FROM AND TREATMENT OF DISEASES INVOLVING PROLIFERATIVE PROCESSES. | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1992-11-19 | — | — | EP | claimed |
| WO-1991011185-A1 | USE OF URAPIDILE AND DERIVATIVES FOR TREATING ARTERIOSCLEROTIC DISEASES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1991-08-08 | — | — | WO | claimed |
| WO-2023192319-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023129857-A1 | METHODS OF TREATING, AMELIORATING, AND/OR PREVENTING STRESS-RELATED DISORDER | YALE UNIVERSITY (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20070219213-A1 | Use of Adrenergic N-Phenylpiperazine Antagonists, Pahrmaceutical Compositions Containning Them, and Methods of Preparing Them | UNIAO BRASILIENSE DE EDUCACAO E CULTURA-UBEC (BR) | 2007-09-20 | — | — | US | disclosed |
| US-20050261214-A1 | Complexes for transferring substances of interest into a cell | TRANSGENE S.A. (FR) | 2005-11-24 | — | — | US | disclosed |
| EP-1389182-A1 | COMPLEXES FOR TRANSFERRING SUBSTANCES OF INTEREST INTO A CELL | TRANSGENE S.A. (FR) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002092554-A1 | COMPLEXES FOR TRANSFERRING SUBSTANCES OF INTEREST INTO A CELL | TRANSGENE S.A. (FR) | 2002-11-21 | — | — | WO | disclosed |
| EP-0689547-A4 | CLONED HUMAN ALPHA1C ADRENERGIC RECEPTOR | MERCK & CO INC (US) | 1998-10-28 | — | — | EP | disclosed |
| EP-0689547-A1 | CLONED HUMAN ALPHA1C ADRENERGIC RECEPTOR | MERCK & CO. INC. (US) | 1996-01-03 | — | — | EP | disclosed |
| WO-1994021660-A1 | CLONED HUMAN ALPHA1C ADRENERGIC RECEPTOR | MERCK & CO., INC. (US) | 1994-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261214-A1 | Complexes for transferring substances of interest into a cell | CD44, EPCAM, ANXA3 | ADRA1A 4309/4885ADRA1B 3765/4885ADRA1D 4458/4885 |
| US-20070219213-A1 | Use of Adrenergic N-Phenylpiperazine Antagonists, Pahrmaceutical Compositions Containning Them, and Methods of Preparing Them | ADRA1D, ADRB1, ADRA1A | ADRA1A 3/4885ADRA1B 4/4885ADRA1D 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.